Dr Robert Seder | Chief of the Cellular Immunology Section
N.I.A.I.D. N.I.H. | United States

Dr Robert Seder, Chief of the Cellular Immunology Section, N.I.A.I.D. N.I.H.

Dr. Seder received his B.A. in Natural Science at Johns Hopkins University in 1981 and his M.D. at Tufts University in 1986, and completed his residency in internal medicine at New York Hospital-Cornell Medical Center. Dr. Seder did his postdoctoral training at NIAID with Dr. William Paul studying how cytokines influence CD4+ T helper cell differentiation. In 1994, Dr. Seder became Chief of the Clinical Immunology Section in the Laboratory of Clinical Investigation, part of the NIAID Division of Intramural Research. Dr. Seder was then appointed to a tenured position in the Vaccine Research Center (VRC), Laboratory of Immunology in 2000. Since joining the VRC, Dr. Seder has focused his efforts on understanding the innate and adaptive mechanisms by which vaccines mediate protective antibody and T cell immunity in mouse, non-human primate models of HIV, Malaria and Tuberculosis infection. A major focus of his laboratory is on vaccine adjuvants and formulation. His recent work in this area has been to develop a nanoparticle neoantigen vaccine for personalized cancer therapy. Over the past several years, Dr. Seder has translated his work in clinical trials in the US and Africa using an attenuated whole sporozoite malaria vaccine for inducing protective immunity in humans. He was the first to demonstrate in humans that intravenous immunization with a vaccine can mediate protection against an infection. Dr. Seder currently serves as chief of the Cellular Immunology Section in the VRC.​

Appearances:



DC Co-conference Day 2 April 4 @ 09:40

Immune profiling in the context of TB and Malaria vaccination

DC Co-conference Day 2 April 4 @ 5:10

Panel Discussion: Tumor neoantigEn SeLection Alliance (TESLA) – discovering the keys to developing personalized cancer vaccines

  • Accurately identifying neo-epitopes
    • What is the diversity of neo-epitope predictions from different groups?
    • How well did these predictions perform in terms of patient sample analysis?
    • Can we identify key parameters that improve the ability to predict neo-epitopes?
  • How do we convert this data into the creation of personalized cancer vaccines?
    • Merits of different vaccines platforms

back to speakers